JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264957

Human ATAD2 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ATAD2 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Western blot - Human ATAD2 knockout HeLa cell line (AB264957)
  • WB

Lab

Western blot - Human ATAD2 knockout HeLa cell line (AB264957)

Lanes 1- 2 : Merged signal (red and green). Green - ab176319 observed at 200 kDa. Red - Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) observed at 50 kDa.

ab176319 was shown to react with ATAD2 in wild-type HeLa cells in western blot. The band observed in knockout cell line ab264957 (knockout cell lysate ab257359) lane below 200kDa may represent truncated forms and cleaved fragments. This has not been investigated further. Wild-type HeLa and ATAD2 knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab176319 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-ATAD2 antibody [EPR12730] (<a href='/en-us/products/primary-antibodies/atad2-antibody-epr12730-ab176319'>ab176319</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

ATAD2 CRISPR/Cas9 edited HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human ATAD2 knockout HeLa cell line (ab264957)

Predicted band size: 159 kDa

Observed band size: 200 kDa

false

Sanger Sequencing - Human ATAD2 knockout HeLa cell line (AB264957)
  • Sanger seq

Unknown

Sanger Sequencing - Human ATAD2 knockout HeLa cell line (AB264957)

Homozygous : 7 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.</p>" } } }

Product details

We will provide viable cells that proliferate on revival.

Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264957-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264957-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264957 Human ATAD2 knockout HeLa cell line", "number":"AB264957-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264957-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264957-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264957 Human ATAD2 knockout HeLa cell line", "number":"AB264957-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264957-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264957 Human ATAD2 knockout HeLa cell line", "number":"AB264957-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264957-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264957 Human ATAD2 knockout HeLa cell line", "number":"AB264957-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ATAD2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ATAD2 also known as ATPase family AAA domain-containing protein 2 is a chromatin-associated AAA ATPase. This protein weighs approximately 157 kDa and functions mainly in the cell nucleus. ATAD2 is widely expressed in various tissues with high levels found in the testis indicating its possible role in testicular functions. It shows ATPase activity involving the hydrolysis of ATP which provides energy for chromatin remodeling processes.
Biological function summary

ATAD2 plays a critical role in transcription regulation by remodeling chromatin structure. As part of a complex it interacts with histone acetylation marks on chromatin therefore influencing gene expression. The protein is often involved in the regulation of genes relevant to cell cycle progression. Its interaction with transcriptional regulators highlights its importance in controlling proliferation and other cellular processes.

Pathways

The role of ATAD2 becomes essential in pathways like the cell cycle and the DNA damage response. Through these pathways it interacts with key proteins such as MYC a known regulator of cell growth and it influences the expression of genes involved in cell cycle control. It is important in maintaining genomic stability by ensuring proper chromatin dynamics during DNA replication and repair.

Aberrant expression of ATAD2 associates with cancer progression particularly in breast cancer where it is highly expressed in MCF7 cell lines. It is also implicated in hepatocellular carcinoma where it interacts with cancer-related proteins such as p53 which is a well-known tumor suppressor. These interactions suggest that ATAD2 serves as a potential target for cancer therapies focused on disrupting its interactions or functions in tumor biology.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com